Literature DB >> 8708174

The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism.

S A Webb1, S Stott, P V van Heerden.   

Abstract

OBJECTIVE: To describe the use of inhaled aerosolized prostacyclin (IAP) in a patient with life-threatening pulmonary hypertension secondary to pulmonary embolism and to discuss the possible use of inhaled prostacyclin in the management of pulmonary embolism.
DESIGN: Case report.
SETTING: Intensive care unit of a university teaching hospital. PATIENTS: One patient with severe pulmonary hypertension secondary to acute-on-chronic pulmonary embolism.
INTERVENTIONS: Conventional medical management of massive pulmonary embolism and inhaled aerosolized prostacyclin (IAP). MEASUREMENTS AND
RESULTS: Description of clinical course, haemodynamic data and gas exchange data.
CONCLUSIONS: We describe a patient with massive pulmonary embolism for whom the addition of IAP to his therapy appeared to result in a transient improvement in pulmonary haemodynamics and gas exchange.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8708174     DOI: 10.1007/BF01700458

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  6 in total

1.  Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction.

Authors:  C Frostell; M D Fratacci; J C Wain; R Jones; W M Zapol
Journal:  Circulation       Date:  1991-06       Impact factor: 29.690

2.  Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

Authors:  L J Rubin; J Mendoza; M Hood; M McGoon; R Barst; W B Williams; J H Diehl; J Crow; W Long
Journal:  Ann Intern Med       Date:  1990-04-01       Impact factor: 25.391

3.  The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease.

Authors:  K M McIntyre; A A Sasahara
Journal:  Am J Cardiol       Date:  1971-09       Impact factor: 2.778

4.  Aerosolised prostacyclin in adult respiratory distress syndrome.

Authors:  D Walmrath; T Schneider; J Pilch; F Grimminger; W Seeger
Journal:  Lancet       Date:  1993-10-16       Impact factor: 79.321

5.  PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.

Authors:  M Welte; B Zwissler; H Habazettl; K Messmer
Journal:  Eur Surg Res       Date:  1993       Impact factor: 1.745

6.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).

Authors:  D K Jones; T W Higenbottam; J Wallwork
Journal:  Br Heart J       Date:  1987-03
  6 in total
  14 in total

1.  Inhaled nitric oxide in patients with pulmonary embolism.

Authors:  J E Tulleken; T S van der Werf; J G Zijlstra; G Capellier; T Jacques; P Balvay; F Barale
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

Review 2.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

3.  No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.

Authors:  Albertus J Kooter; Richard G Ijzerman; Otto Kamp; Anco B Boonstra; Yvo M Smulders
Journal:  BMC Pulm Med       Date:  2010-03-30       Impact factor: 3.317

4.  Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism.

Authors:  Vincent Ganière; François Feihl; Damien Tagan
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

Review 5.  New approaches to the treatment of pulmonary hypertension: from bench to bedside.

Authors:  Subramanyam N Murthy; Bobby D Nossaman; Philip J Kadowitz
Journal:  Cardiol Rev       Date:  2010 Mar-Apr       Impact factor: 2.644

6.  Toxicity of prolonged high dose inhaled PGE1 in ventilated neonatal pigs.

Authors:  Beena G Sood; Elizabeth J Dawe; Krishna Rao Maddipati; Monica Malian; Xinguang Chen; Robert Galli; Raja Rabah
Journal:  Pulm Pharmacol Ther       Date:  2008-02-06       Impact factor: 3.410

Review 7.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

8.  Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I/II open label clinical trial.

Authors:  Beena G Sood; Virginia Delaney-Black; Jacob V Aranda; Seetha Shankaran
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

Review 9.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

10.  Management of massive and nonmassive pulmonary embolism.

Authors:  Vishal Sekhri; Nimeshkumar Mehta; Naveen Rawat; Stuart G Lehrman; Wilbert S Aronow
Journal:  Arch Med Sci       Date:  2012-12-19       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.